Objective — to improve quality of life, by reducing the rate of recurrences in patients with herpesvirus type 2 infection. Subject and methods. 95 patients with recurrent genital herpes were examined. All the patients underwent serology testing for IgM, IgA, and IgG antibodies, immunoglobulin G avidity, and herpesvirus type 2 antigen in the vaginal and cervical mucosal scrapings, by using a polymerase chain reaction assay. Results. Only in 7 patients, the clinical manifestations of genital herpes in the history occurred once during a year; the remaining 88 patients had more frequent exacerbations mainly in autumn and spring. 57 (60%) patients with elevated IgG levels were identified. For the prevention and treatment of recurrent herpes virus type 2 infection, the Russian drug Panavir was used as rectal suppositories 200 mg every 24 hours overnight for 10 consecutive days. After the first treatment cycle, it was recommended that antirecurrent therapy cycles be performed once every 6 months in autumn and spring (October, March), by administering 5 rectal panavir suppositories on days 1, 3, 5, 8, and 11 of the menstrual cycle during 24 months. Among those who completed a follow-up survey, 75.3% of the patients had no recurrence within 24 months, 21.3% had one recurrence, 3.2% had 2 recurrences, and one case had 3 recurrences. The therapeutic efficiency was 96.6%. Conclusion. The results of the study allow antirecurrent therapy with rectal panavir suppositories to be recommended for patients with genital herpes once every 6 months in autumn and spring according to the proposed regimen.